Sunday 18 October 2026
Export NUVOQ’s income statement to Excel — free account
Holdco Nuvo Group D.G Ltd.
NUVOQ Healthcare Medical Devices
Holdco Nuvo Group D.G Ltd.’s revenue for fiscal 2023 (year ended December 2023) was $176,000.00.
0.00
0.00
NaN
Follow NUVOQ
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Trend | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 9.72 | 9.41 |
Analyst estimates 2024–2026 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 10.71 | 11.66 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 3 | 3 | 59 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 0 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | (8.52) | |||||
| EBT | — | — | — | — | — | — | — | (34) | (20) | (35) | |||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | (19,712.50) | |||||
| Net income | — | — | — | 0 | — | — | — | (35) | (21) | (34) | |||||
| Depreciation | — | — | — | — | — | — | — | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.01 | ||||
| Earnings | — | — | — | — | — | — | — | (2.03) | (1.21) | (1.86) | |||||
| Cash flow | — | — | — | — | — | — | — | (0.85) | (0.79) | (0.83) | |||||
| Capex | — | — | — | — | — | — | — | (0.01) | (0.01) | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | — | (0.86) | (0.81) | (0.83) | |||||
| Book value | — | — | — | — | — | — | — | (0.51) | (2.27) | (3.74) | |||||
| Shares, m | — | — | — | — | — | — | — | 17 | 17 | 18 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (13.73) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (14) | (13) | (15) | ||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | — | (15) | (14) | (15) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 1 | (39) | (29) | ||||
| Total debt | — | — | — | — | — | — | — | — | 9 | 12 | |||||
| Net debt | — | — | — | — | — | — | — | (1) | 8 | 11 | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | (9) | (39) | (67) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | (13.15) | (15.54) | (930.47) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | — | (28.67) | 87.36 | 63.38 | |||||
Negative figures in brackets.
Fiscal years to Dec 2023
Charts ten years each
Holdco Nuvo Group D.G Ltd. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADGM Adagio Medical Holdings, Inc. | $2.8M | — (loss-making) | — | −33.50% (below 0%: shrinking) | n/m | −12.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IVF INVO Fertility, Inc | $2.8M | 0.0× | — (loss-making) | +16.73% (above 0%: growing) | n/m | +35.07% (above 0%: growing) | 35.06% | (59.28%) | Compare |
| NXL Nexalin Technology, Inc. | $2.6M | — (loss-making) | — (loss-making) | −82.72% (below 0%: shrinking) | n/m | −97.23% (below 0%: shrinking) | 72.95% | (18,420.49%) | Compare |
| BIOLQ Biolase, Inc. | $2.3M | — (loss-making) | — (loss-making) | −0.65% (below 0%: shrinking) | n/m | −60.22% (below 0%: shrinking) | 40.39% | (6.41%) | Compare |
| XAIR Beyond Air, Inc. | $2.2M | — (loss-making) | — (loss-making) | +0.45% (above 0%: growing) | n/m | −9.10% (below 0%: shrinking) | 12.73% | (373.98%) | Compare |
| NUVOQ Holdco Nuvo Group D.G Ltd. | $2.1M | — (loss-making) | — | — | n/m | −1.05% (below 0%: shrinking) | 0.00% | 0.00% | |
| VJET Flyte Aviation, Inc. | $2.1M | — (loss-making) | — (loss-making) | +380.66% (above 0%: growing) | n/m | −26.70% (below 0%: shrinking) | 9.62% | (388.13%) | Compare |
| NUWE Nuwellis, Inc. | $2.0M | — (loss-making) | — (loss-making) | +14.14% (above 0%: growing) | n/m | −51.55% (below 0%: shrinking) | 76.08% | (160.94%) | Compare |
| AFIB Acutus Medical, Inc. | $1.7M | — (loss-making) | — (loss-making) | +204.18% (above 0%: growing) | n/m | +76.40% (above 0%: growing) | 14.20% | (3.81%) | Compare |
| Median of peers | $2.3M | — | — | +7.30% | — | −19.78% | 24.63% | (110.11%) |
Holdco Nuvo Group D.G Ltd. (NUVOQ) key facts
- Holdco Nuvo Group D.G Ltd. (NUVOQ) is a Medical Devices company in the Healthcare sector.
- Holdco Nuvo Group D.G Ltd.’s revenue for fiscal 2023 (year ended December 2023) was $176,000.00.
- Return on equity was 63.4% and debt-to-equity -0.17.
- Its Altman Z-score is −81.90 (distress zone) for fiscal 2023.